

Barbara M King

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3695640/barbara-m-king-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29 papers	620 citations	15 h-index	24 g-index
29 ext. papers	668 ext. citations	4 avg, IF	3.06 L-index

#	Paper	IF	Citations
29	Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA. <i>Brain Research</i> , 2006 , 1104, 1-17	3.7	79
28	Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice. <i>Molecular Genetics and Metabolism</i> , 2007 , 90, 313-28	3.7	75
27	Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease. <i>European Journal of Neuroscience</i> , 2009 , 29, 1197-214	3.5	58
26	Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs--a proof of principle study. <i>Molecular Genetics and Metabolism</i> , 2009 , 98, 383-92	3.7	50
25	Enzyme replacement reduces neuropathology in MPS IIIA dogs. <i>Neurobiology of Disease</i> , 2011 , 43, 422-34	3.5	43
24	Enzyme replacement therapy in Mucopolysaccharidosis VI: evidence for immune responses and altered efficacy of treatment in animal models. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 1997 , 1361, 203-16	6.9	28
23	Validation of a heparan sulfate-derived disaccharide as a marker of accumulation in murine mucopolysaccharidosis type IIIA. <i>Molecular Genetics and Metabolism</i> , 2006 , 87, 107-12	3.7	27
22	Delivery of therapeutic protein for prevention of neurodegenerative changes: comparison of different CSF-delivery methods. <i>Experimental Neurology</i> , 2015 , 263, 79-90	5.7	24
21	Purification and characterization of recombinant human lysosomal alpha-mannosidase. <i>Molecular Genetics and Metabolism</i> , 2001 , 73, 18-29	3.7	24
20	Treatment of canine fucosidosis by intracisternal enzyme infusion. <i>Experimental Neurology</i> , 2011 , 230, 218-26	5.7	23
19	Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice. <i>Molecular Genetics and Metabolism</i> , 2015 , 115, 33-40	3.7	20
18	Neonatal Bone Marrow Transplantation in MPS IIIA Mice. <i>JIMD Reports</i> , 2013 , 8, 121-32	1.9	18
17	Enzyme replacement therapy in alpha-mannosidosis guinea-pigs. <i>Molecular Genetics and Metabolism</i> , 2006 , 89, 48-57	3.7	18
16	Evaluation of enzyme dose and dose-frequency in ameliorating substrate accumulation in MPS IIIA Huntaway dog brain. <i>Journal of Inherited Metabolic Disease</i> , 2015 , 38, 341-50	5.4	17
15	Caprine mucopolysaccharidosis IIID: a preliminary trial of enzyme replacement therapy. <i>Journal of Molecular Neuroscience</i> , 2000 , 15, 251-62	3.3	16
14	Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA. <i>Journal of Neurochemistry</i> , 2016 , 137, 409-22	6	13
13	Disease stage determines the efficacy of treatment of a paediatric neurodegenerative disease. <i>European Journal of Neuroscience</i> , 2014 , 39, 2139-50	3.5	12

12	Slow, continuous enzyme replacement via spinal CSF in dogs with the paediatric-onset neurodegenerative disease, MPS IIIA. <i>Journal of Inherited Metabolic Disease</i> , 2017 , 40, 443-453	5.4	11
11	Low-dose, continual enzyme delivery ameliorates some aspects of established brain disease in a mouse model of a childhood-onset neurodegenerative disorder. <i>Experimental Neurology</i> , 2016 , 278, 11-21	5.7	11
10	Immune response to enzyme replacement therapy: clinical signs of hypersensitivity reactions and altered enzyme distribution in a high titre rat model. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 1998 , 1407, 163-72	6.9	10
9	AAVrh10 Vector Corrects Disease Pathology in MPS IIIA Mice and Achieves Widespread Distribution of SGSH in Large Animal Brains. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020 , 17, 174-187	6.4	10
8	A novel conditional Sgsh knockout mouse model recapitulates phenotypic and neuropathic deficits of Sanfilippo syndrome. <i>Journal of Inherited Metabolic Disease</i> , 2017 , 40, 715-724	5.4	8
7	Caprine mucopolysaccharidosis IIID: fetal and neonatal brain and liver glycosaminoglycan and morphological perturbations. <i>Journal of Molecular Neuroscience</i> , 2004 , 24, 277-91	3.3	7
6	Recombinant caprine 3H-[N-acetylglucosamine-6-sulfatase] and human 3H-[N-acetylgalactosamine-4-sulfatase]: plasma clearance, tissue distribution, and cellular uptake in the rat. <i>Journal of Molecular Neuroscience</i> , 1998 , 11, 223-32	3.3	6
5	Synthetic Disaccharide Standards Enable Quantitative Analysis of Stored Heparan Sulfate in MPS IIIA Murine Brain Regions. <i>ACS Chemical Neuroscience</i> , 2019 , 10, 3847-3858	5.7	5
4	EMannosidosis in German Shepherd Dogs. <i>Veterinary Pathology</i> , 2019 , 56, 743-748	2.8	3
3	Sulfate transport in normal and cystic fibrosis fibroblasts. <i>Biochemical Medicine and Metabolic Biology</i> , 1992 , 47, 260-4		2
2	MUCOPOLYSACCHARIDOSIS II (MPS II) IN A FREE-LIVING KAKA (NESTOR MERIDIONALIS) IN NEW ZEALAND. <i>Journal of Wildlife Diseases</i> , 2021 , 57, 884-890	1.3	1
1	Is SGSH heterozygosity a risk factor for early-onset neurodegenerative disease?. <i>Journal of Inherited Metabolic Disease</i> , 2021 , 44, 763-776	5.4	1